All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 66 points (0.4%) at 14,999 as of Wednesday, July 3, 2013, 12:51 PM ET. The NYSE advances/declines ratio sits at 1,256 issues advancing vs. 1,690 declining with 89 unchanged. The Drugs industry currently sits down 0.1% versus the S&P 500, which is up 0.2%. On the negative front, top decliners within the industry include Valeant Pharmaceuticals International ( VRX), down 1.1%, and Eli Lilly and Company ( LLY), down 0.9%. Top gainers within the industry include Vertex Pharmaceuticals ( VRTX), up 1.5%, Celgene Corporation ( CELG), up 1.2% and Biogen Idec ( BIIB), up 0.6%. TheStreet would like to highlight 5 stocks pushing the industry lower today: 5. Dr. Reddy Laboratories ( RDY) is one of the companies pushing the Drugs industry lower today. As of noon trading, Dr. Reddy Laboratories is down $1.14 (-3.0%) to $37.08 on heavy volume. Thus far, 268,628 shares of Dr. Reddy Laboratories exchanged hands as compared to its average daily volume of 230,200 shares. The stock has ranged in price between $36.82-$37.32 after having opened the day at $36.97 as compared to the previous trading day's close of $38.22. Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company. It operates in three segments: Pharmaceutical services and Active Ingredients (PSAI), Global Generics, and Proprietary Products. Dr. Reddy Laboratories has a market cap of $6.5 billion and is part of the health care sector. Shares are up 14.8% year to date as of the close of trading on Tuesday. Currently there are 2 analysts that rate Dr. Reddy Laboratories a buy, no analysts rate it a sell, and 2 rate it a hold. TheStreet Ratings rates Dr. Reddy Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Dr. Reddy Laboratories Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.